Solid Biosciences Inc. Other Noncash Income (Expense)
Solid Biosciences Inc. (SLDB) reported Other Noncash Income (Expense) of -$25.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-06
- Solid Biosciences Inc. other noncash income (expense) for the quarter ending 2026-06-30 was -$25.00K.
- Solid Biosciences Inc. other noncash income (expense) for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Solid Biosciences Inc. other noncash income (expense) for the quarter ending 2025-12-31 was $0.00.
- Solid Biosciences Inc. other noncash income (expense) for the quarter ending 2025-09-30 was $294.00K.
- Solid Biosciences Inc. other noncash income (expense) for fiscal 2025 was $239.00K, a 171.59% increase from fiscal 2024.
- Solid Biosciences Inc. other noncash income (expense) for fiscal 2024 was $88.00K.
- Solid Biosciences Inc. other noncash income (expense) for fiscal 2023 was -$374.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$25.00K 10-Q · filed 2026-08-06 | -$25.00K derived: sum of 3 quarters · filed 2026-08-06 | $269.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $294.00K derived: sum of 3 quarters · filed 2026-05-12 | $217.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $294.00K derived: sum of 2 quarters · filed 2026-03-19 | $217.00K derived: sum of 3 quarters · filed 2026-08-06 | $239.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $294.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $217.00K derived: sum of 2 quarters · filed 2026-08-06 | $239.00K 10-Q · filed 2025-11-03 | $237.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$77.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$55.00K 10-Q · filed 2026-08-06 | -$57.00K derived: sum of 3 quarters · filed 2026-08-06 | -$61.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $22.00K 10-Q · filed 2026-05-12 | $20.00K derived: sum of 2 quarters · filed 2026-05-12 | $16.00K derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$6.00K derived: sum of 2 quarters · filed 2026-03-19 | $88.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $90.00K 10-Q · filed 2025-11-03 | ||
| 2024-06-30 | $94.00K 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | -$374.00K 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |